Protocol for MIR 5420, 5520, 5620, 5320

SDS and Certificate of Analysis available at mirusbio.com/5320



INTRODUCTION

The pLIVE® vector (<u>Liver In Vivo Expression</u>) is designed for high level, prolonged expression of transgenes in the mouse liver. This vector utilizes a chimeric promoter composed of the mouse alpha fetoprotein enhancer II and the minimal mouse albumin promoter. Two introns have been engineered into the vector to increase the expression of the delivered transgene. Downstream of the first intron is a multiple cloning site (MCS) with eight unique restriction sites allowing for simple insertion of the gene of interest. Together the chimeric promoter and two introns are capable of promoting high level transgene expression in the liver for extended lengths of time compared to classic promoters such as the CMV immediate early promoter.

In addition to the pLIVE® Vector, two reporter vectors derived from pLIVE®, pLIVE®-lacZ (encoding β -galactosidase) and pLIVE®-SEAP (encoding \underline{S} ecreted \underline{E} mbryonic \underline{A} lkaline \underline{P} hosphatase), were created for use as positive controls. Expression of lacZ can be monitored in the liver using either classical X-gal staining of liver sections or quantitative β -galactosidase assays of liver lysates. Expression of the SEAP gene from pLIVE®-SEAP can be easily monitored using a quantitative assay of mouse serum. The high level, long term liver-specific expression of transgenes from the pLIVE®-lacZ and pLIVE®-SEAP Reporter Vectors make the pLIVE® Vector series the ideal choice for *in vivo* liver expression studies in mice.

SPECIFICATIONS

Concentration	Each vector DNA is supplied at 1 mg/ml in TE buffer (10 mM Tris, pH 7.5, 0.1 mM EDTA)	
Storage	Store vector DNA at -20°C. Prior to use, thaw at room temperature, vortex and quick spin in a microcentrifuge.	
Product Guarantee Guaranteed for 1 year from the date of purchase, when prostored and handled.		

MATERIALS

Materials Supplied


The pLIVE® Vectors are supplied in *one* of the following formats:


Product Name	Product No.	Quantity	Component(s)
pLIVE® Vector	MIR 5420	20 μg	pLIVE® Vector
pLIVE® Vector/lacZ Control Vector Kit	MIR 5520	20 μg each	pLIVE® and pLIVE®- <i>lacZ</i> Vectors
pLIVE® Vector/SEAP Control Vector Kit	MIR 5620	20 μg each	pLIVE® and pLIVE®-SEAP Vectors
pLIVE® Vector Complete System (All 3 Vectors) MIR 5320		20 μg each	pLIVE®, pLIVE®-lacZ and pLIVE®-SEAP Vectors

For Research Use Only




VECTOR MAPS





Protocol for MIR 5420, 5520, 5620, 5320





Footure	Vector (bp position)		
Feature	pLIVE®	pLIVE®-lacZ	pLIVE®-SEAP
Vector Size (bp)	3423	6509	4992
Mouse Alpha Fetoprotein Enhancer II	8 – 226	8 – 226	8 – 226
Mouse Minimal Albumin Promoter	269 – 586	269 – 586	269 – 586
Intron 1	602 – 900	602 – 900	602 – 900
MCS (NheI/ AscI/ SalI/ SmaI/ BamHI/ SacI/ SacII/ XhoI)*	908 – 961	n/a	n/a
E. coli lacZ Coding Sequence	n/a	978 – 4034	n/a
Human Placental Secreted Alkaline Phosphatase (SEAP) ORF	n/a	n/a	933 – 2489
Intron 2	988 – 1329	4074 – 4415	2557 – 2898
Polyadenylation Region	1472 – 1805	4558 – 4891	3041 – 3374
Kanamycin Resistance Gene	1888 – 2683	4974 – 5768	3457 – 4251
pUC Origin	2746 – 3334	5832 - 6420	4315 – 4903

^{*}MCS (Multiple Cloning Sites) restriction enzyme sites can be used for the insertion of the gene of interest

Protocol for MIR 5420, 5520, 5620, 5320



DISCLAIMER

For research use only. Small-animal research is regulated by federal laws and regulations. Extensive information on this topic is provided by the NIH Office for Protection from Research Risks (http://www.hhs.gov/ohrp/). This kit does not confer any approval from regulatory agencies to conduct animal research. Follow all applicable laws and regulations pertaining to the care and use of animals in research. All personnel who handle animals should be properly trained. Familiarity with performing tail vein injections in your particular mouse species will greatly facilitate this procedure.

CLONING THE GENE OF INTEREST (GOI) INTO THE pLIVE® VECTOR

Clone the GOI into the MCS (Figure 1.) of the pLIVE® Vector using standard molecular biology techniques. For detailed information on cloning, see Current Protocols in Molecular Biology¹ or Molecular Cloning: A Laboratory Manual².

Figure 1. DNA Sequence of the pLIVE® Vector MCS



A. Compatible Restriction Enzymes

Many of the overhangs produced by the restriction enzymes in this MCS are compatible with the overhangs produced by other restriction enzymes.

*Nhe*I is compatible with *Avr*II, *Spe*I, *Sty*I (C/CTAGG) and *Xba*I.

AscI is compatible with AfIIII (A/CGCGT) and MluI.

SalI is compatible with PspXI and XhoI.

SmaI produces a blunt end and can be ligated to any other blunt-ended fragment. XmaI also cuts at the SmaI recognition sequence and produces a 5' overhang that is compatible with AgeI, BsaWI, BspEI, BsrFI, NgoMIV and SgrAI.

BamHI is compatible with BclI and BglII.

SacII is compatible with BsiEI.

*Xho*I is compatible with *Sal*I.

B. General Cloning Architecture

When cloning the GOI fragment into the MCS of the pLIVE® Vector, be certain to include a stop codon at the 3' end of the GOI open reading frame and design the sequence around the ATG start codon (underlined) such that it matches the Kozak translational consensus sequence: (G/A)NNATGG^{3,4}. This consensus sequence will promote the optimal translation efficiency of the GOI mRNA.

 Due to the presence of intron 2 downstream of the MCS, cloning a GOI such that the stop codon is more than 50 bp upstream of the 5' end of intron 2 could induce nonsense mediated decay (NMD) of the GOI mRNA^{5,6} and reduce expression. In order to avoid

Page 4 of 8

Protocol for MIR 5420, 5520, 5620, 5320



NMD, clone the GOI open reading frame into the MCS such that the 3' end of the ORF is within 50 bp of the 5' end of intron 2 (bp 988). If the GOI 3' end restriction site is engineered immediately downstream of the GOI stop codon, the fragment can be cloned into the *Sac*I, *Sac*II or *Xho*I sites and the stop codon will be within 50 bp of the 5' end of intron 2.

2. The 5' end of the GOI ORF can be cloned using any of the restriction sites in the MCS.

C. Confirm Sequence

If the GOI fragment was generated by polymerase chain reaction (PCR) before cloning into the pLIVE® Vector, it is important to sequence the entire cloned GOI fragment to verify that no detrimental mutations were introduced during PCR amplification.

PREPARATION OF PLASMID DNA FOR DELIVERY

Once the correct clone has been identified and verified, amplify the vector DNA in a suitable E. coli strain such as DH5 α or DH10b using 30 µg/ml kanamycin sulfate in the culture media for plasmid selection. Use a plasmid purification system that results in vector DNA with endotoxin (lipopolysaccharides, pyrogens) levels that are <30 EU/mg of DNA which are suitable for $in\ vivo$ delivery. If the pLIVE®-lacZ and pLIVE®-SEAP Reporter Vectors are going to be used for animal studies, they will have to be amplified in E. coli as well using the same procedure.

HYDRODYNAMIC TAIL VEIN INJECTIONS

As a leader in the development of the highly efficient hydrodynamic tail vein injection procedure for the delivery of nucleic acids, Mirus Bio uses and recommends this technique for the delivery of nucleic acids to the liver.

Deliver the pLIVE® Vector DNA (pLIVE®-GOI, pLIVE®-lacZ, or pLIVE®-SEAP) to the mouse liver using the hydrodynamic tail vein injection procedure developed by Mirus Bio (See Related Products Section). Normally, 10-50 µg of plasmid DNA per mouse is delivered using this technique and the amount injected will ultimately depend on the level of expression necessary for the experiment. The hydrodynamic tail vein injection procedure is explained in detail in the *TransIT®-QR* (MIR 5240)* and *TransIT®-EE* (MIR 5340)* Hydrodynamic Delivery Solution protocols (https://www.mirusbio.com/5240). The *TransIT®-QR* Hydrodynamic Delivery Solution (MIR 5240)* is optimized for efficient delivery of naked nucleic acids, including the pLIVE® Vectors, to the liver, with the additional benefit that the injected mice demonstrate quick recovery post-injection compared to animals injected using normal saline as the delivery solution. The *TransIT®-EE* Hydrodynamic Delivery Solution (MIR 5340)* is formulated to promote enhanced expression from plasmid expression vectors such as the pLIVE® Vectors after delivery to the liver using hydrodynamic tail vein injections. The expression level obtained using the *TransIT®-EE* Delivery Solution is approximately 2-3 fold greater than the level of expression obtained after delivery of DNA using the *TransIT®-QR* Delivery Solution.



If the plasmid DNA is contaminated with endotoxin, the MiraCLEAN™ Endotoxin Removal Kit (MIR 5900 or MIR 5910) can be used to easily remove the unwanted endotoxin.



For additional information about hydrodynamic tail vein injections, call the Mirus Bio technical support team at 1.888.530.0801 or email techsupport@mirusbio.com. An online instructional video of the hydrodynamic tail vein injection procedure is also available.



The pLIVE® Vectors can be used in conjunction with any delivery technique that will deliver the vector DNA to the mouse liver efficiently.

Protocol for MIR 5420, 5520, 5620, 5320



DETECTION OF GENE EXPRESSION AFTER DELIVERY

A. Detection of *lacZ* Gene Expression from the pLIVE®-*lacZ* Vector in the Liver

Liver lacZ expression from the pLIVE®-lacZ Vector can be detected using two different methods. Liver tissue sections can be stained with X-gal, turning the β -galactosidase positive (lacZ expressing) cells blue. This assay is useful when a measure of vector delivery efficiency is important or a visual readout of delivery is desired.

LacZ expression can also be quantified in liver lysates using a chemiluminescent assay, such as the Galacto-LightTM Kit (Applied Biosystems). As a general recommendation, livers should be harvested and lysed in approximately 4 ml of lysis buffer. The liver lysates should then be diluted 100-500 fold before being assayed to ensure accurate quantification.

B. Detection of SEAP Gene Expression from the pLIVE®-SEAP Vector in the Liver

SEAP expression from the pLIVE®-SEAP Vector can be detected in the serum of mice using a quantitative chemiluminescent assay, such as the Phospha-Light™ Kit (Applied Biosystems). Serum samples may require approximately 80-300 fold dilution depending on the amount of Vector DNA delivered and the expression level of SEAP obtained.

REFERENCES

- Ausubel, F.M. et al. (2005) Current Protocols in Molecular Biology John Wiley & Sons, Inc. Hoboken, New Jersey.
- Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, New York.
- 3. Kozak, M. (1987) Nuc. Acids Res. 15:8125-8148.
- 4. Kozak, M. (1991) J. Cell Biol. 115:887-903.
- 5. Beyers, P.H. (2002) J. Clin. Invest. 109:3-6.
- 6. Baker, K.E. and R. Parker (2004) Curr. Opin. Cell Biol. 16:293-299.



Optimal transgene expression from the pLIVE® Vectors generally occurs 3-5 days post-delivery.

Protocol for MIR 5420, 5520, 5620, 5320



TROUBLESHOOTING GUIDE

POOR EXPRESSION OF THE GENE OF INTEREST (GOI)				
Problem	Solution			
Poor delivery of the pLIVE® Vector	Poor delivery will result in low levels of expression from a pLIVE® Vector. If using the hydrodynamic tail vein injection, be certain to inject the full volume of the nucleic acids solution rapidly (4-7 seconds) with steady pressure into the tail vein. For more details on hydrodynamic delivery, consult the <i>Trans</i> IT®-QR Hydrodynamic Delivery Solution protocol (https://www.mirusbio.com/5240) or contact Mirus Bio technical support at 1.888.530.0801 or techsupport@mirusbio.com. Use pLIVE®-lacZ or pLIVE®-SEAP Reporter Vectors to verify that the delivery technique, including proper hydrodynamic tail vein injection.			
Poor translational context surrounding the ATG start codon of the GOI	The best translation efficiency in mammalian cells is usually obtained when the sequence surrounding the ATG start codon of the gene of interest has the following sequence: (G/A) NN <u>ATG</u> G ^{3,4} .			
Suboptimal location of the GOI stop codon in the pLIVE® Vector MCS	If the stop codon of the GOI open reading frame is more than 50 bp upstream of the 5' end of intron 2 (bp 988), nonsense mediated decay could be induced in the cell, leading to a decreased level of the GOI mRNA in the cell ^{5,6} . We have seen a 2-3 fold decrease in the level of luciferase expression when the luciferase stop codon is more than 50 bp upstream of the start of intron 2.			
Suboptimal amount of pLIVE® Vector DNA delivered	Increase the amount of vector DNA delivered. Using the pLIVE®-lacZ or pLIVE®-SEAP Vectors, scientists at Mirus Bio routinely deliver 10 µg of vector DNA per mouse and observe robust expression of the reporter genes using the hydrodynamic tail vein injection procedure.			
Protein product expressed from the delivered transgene induces an immune response in the mouse	If the transgene protein product is immunogenic in mice, it will induce an immune response which will ultimately lead to the clearance of the liver cells expressing the transgene. An immune response in the mice will usually be indicated by a rapid decrease in the level of expression from the delivered pLIVE® Vector 10-14 days post-delivery. Harvest the mouse livers at earlier timepoints post-injection and reassay for expression. Alternatively, use C57Bl/6 mice which tend to be less immune-responsive to closely related human genes.			
DIFFICULTY WORKING WITH THE pLIVE® VECTORS				
Problem	Solution			
No transformants obtained with a pLIVE® Vector	The various pLIVE® Vectors contain a kanamycin selectable marker. Be certain to propagate the <i>E. coli</i> cells harboring the pLIVE® Vectors in liquid and solid media containing 30 μg/ml kanamycin sulfate to select for maintenance of the vector. DO NOT USE ampicillin.			
Poor plasmid yields from plasmid preparations	The vector backbone of the pLIVE® Vectors is derived from pUC, a high copy number plasmid When purifying plasmid DNA using Qiagen's Maxiprep Kit or Marligen's High Purity Plasmid Maxiprep Kit, use 100 ml of an LB + 30 μ g/ml kanamycin liquid culture. Using the Marligen High Purity Plasmid Maxiprep Kit, a yield of 750 μ g of pLIVE® Vector DNA is routinely obtained from 100 ml of bacterial culture.			

Call Mirus Bio Technical Support Team at 1.888.530.0801 or email <u>techsupport@mirusbio.com</u> for access to an online instructional video for performing tail vein injections and any specific questions or concerns.

Protocol for MIR 5420, 5520, 5620, 5320



RELATED PRODUCTS

- MiraCLEAN® Endotoxin Removal Kit
- TransIT®-EE Hydrodynamic Delivery Solution
- TransIT®-QR Hydrodynamic Delivery Solution

For details on our products, visit www.mirusbio.com

Contact Mirus Bio for additional information.



Mirus Bio LLC 5602 Research Park Blvd, Ste 210 Madison, WI 53719

Toll-free: 888.530.0801 Direct: 608.441.2852 Fax: 608.441.2849

©1996-2024 All rights reserved. Mirus Bio LLC. All trademarks are the property of their respective owners. For terms and conditions, visit www.mirusbio.com

Rev1 03272023 Page 8 of 8